ClinicalTrials.gg
CompletedNCT01246986Updated Jan 12, 2021Results posted

A Study of LY2157299 in Participants With Hepatocellular Carcinoma

A Phase 2 interventional study of LY2157299 and Sorafenib in Carcinoma, Hepatocellular, sponsored by Eli Lilly and Company. Completed at 40 sites in 7 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-01-12.

Sponsored by Eli Lilly and Company · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
204
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 13 studies in Carcinoma, Hepatocellular by Eli Lilly and Company — none open to participants now, none under way, none of them phase 3. Carcinoma, Hepatocellular · Eli Lilly and Company.

Enrollment
3rd of 13
204 · median 47
Started
2011
the only one that year
Phase 2
4 of 13
none open now
Registered
5th of 13
by date

Among the 13 studies in Carcinoma, Hepatocellular by Eli Lilly and Company, this one is the 3rd largest by enrollment, is the only one that started in 2011, is one of 4 in phase 2, and was the 5th registered.

Carcinoma, Hepatocellular

3,651 studies on the registry are indexed under Carcinoma, Hepatocellular; 1,063 are open to participants now.

Browse Carcinoma, Hepatocellular studies →

Open to participants now

None of the 13 studies in Carcinoma, Hepatocellular by Eli Lilly and Company is open now. The open studies under Carcinoma, Hepatocellular, anywhere →

Who these studies take

Of the 739 Carcinoma, Hepatocellular studies recruiting now, 383 (52%) set no upper age limit and 249 (34%) stop at 75 or younger; 31 take children under 18; 31 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 13 studies in Carcinoma, Hepatocellular by Eli Lilly and Company as a file.
02

Study summary

The purpose of this study is to estimate the median time to progression in participants with hepatocellular carcinoma (HCC) when treated with LY2157299 as monotherapy and in combination with sorafenib or ramucirumab.

Read the detailed description

The study consists of four Parts: Part A where HCC participants with an increased alpha-fetoprotein (AFP) level will be treated with either 160 milligrams (mg) LY2157299 or 300 mg LY2157299. Part B where HCC participants with a normal AFP level will be treated with 300 mg LY2157299, Part C where treatment-naïve HCC participants will be treated with 160 mg LY2157299 + sorafenib or 300 mg LY2157299 + sorafenib, and Part D where HCC participants will be treated with either 160 mg or 300 mg LY2157299 + ramucirumab.

Participants who continue to receive benefit from treatment at the time that the study is considered completed, may enter the treatment extension period and continue to receive the study treatment. The end of the study is the date of last visit or last scheduled procedure for the last active subject in the study.

03

Conditions studied

  • Carcinoma, Hepatocellular
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Have histological evidence of a diagnosis of HCC not amenable to curative surgery
  • Part A: Serum alpha fetoprotein greater than or equal to 1.5 , Part B: Serum alpha fetoprotein less than 1.5 Upper Limits of Normal. Not applicable for Part C or D
  • Stage: A or B7 for Parts A \& B, A for Part C, and D
  • Have the presence of as defined by the (RECIST 1.1). A lesion that has been previously treated by local therapy will qualify as a measurable or evaluable lesion if there was demonstrable progression following locoregional therapy
  • Have given written prior to any study-specific procedures
  • Have adequate hematologic, hepatic and renal function
  • Have a performance status of equal to or less than 1 on the (ECOG) scale
  • For Parts A \& B: Have received sorafenib and have progressed or were intolerant to sorafenib or are ineligible for sorafenib treatment. For Part C: not received previous systemic treatment. For Part D: have received sorafenib and have progressed or were intolerant to sorafenib or are ineligible for sorafenib treatment or have not received prior systemic treatment.
  • For Parts A, B, and D: have discontinued sorafenib for at least 2 weeks
  • Are reliable and willing to make themselves available for the duration of the study and are willing to follow study procedures
  • Males and females with must agree to use medically approved precautions during the trial and for 3 months following the last dose of study drug
  • Females with must have had a negative serum pregnancy test less than or equal to 7 days prior to the first dose of study drug
  • Are able to swallow capsules or tablets

Exclusion criteria

Exclusion Criteria:

  • Are currently enrolled in, or discontinued within the last 28 days from a clinical trial involving an drug or device or not approved use of a drug or device (other than the study drug used in this study), or concurrently enrolled in any other type of medical research judged not to be scientifically or medically compatible with this study
  • Known HCC with fibro-lamellar or mixed histology
  • Presence of ascites
  • History of liver transplant requiring increased therapy. (Participants on maintenance immunosuppressive therapy after liver transplant are eligible for Part A \& B)
  • Have received more than 1 in Parts A, B and D
  • Have moderate or severe cardiac disease:

    1. Have the presence of cardiac disease, including a myocardial infarction within 6 months prior to study entry, unstable angina pectoris, (NYHA) Class III/IV congestive heart failure, or uncontrolled hypertension
    2. Have documented major (ECG) abnormalities at the investigator's discretion
    3. Have major abnormalities documented by echocardiography with Doppler
    4. Have predisposing conditions that are consistent with development of aneurysms of the ascending aorta or aortic stress
  • Have serious preexisting medical conditions that, in the opinion of the investigator, that cannot be adequately controlled with appropriate therapy or would preclude participation in this study
  • Females who are pregnant or lactating
  • Have a history of any other cancer (except non-melanoma skin cancer or carcinoma in-situ of the cervix) unless in complete remission and off all therapy for that disease for a minimum of 3 years. At the discretion of the investigator, hormone- prostate cancer participants who are stable on GnRH agonist therapy and breast cancer participants who are stable on antiestrogen therapy may have that treatment continued
  • Have active infection that would interfere with the study objectives or influence study compliance
  • For Part C, have a known to sorafenib or its
  • For Part D, have a serious illness or medical condition(s), including but not limited to the following:

    1. The participant has undergone major surgery within 28 days prior to randomization or has undergone central venous access device placement within 7 days prior to randomization
    2. The participant has uncontrolled arterial hypertension ≥150 / ≥90 millimeters of mercury (mm Hg) despite standard medical management
Terms in these criteria, in plain language(18)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
204 participants (actual)

Study arms

  • Experimental
    Part A Cohort 1-160 milligram (mg) LY2157299

    Per the protocol, following an interim analysis, the decision was taken to no longer randomize participants to the 160 mg LY2157299 arm. As of May 25,2012, all newly enrolled participants will receive 300 mg LY2157299. 80 mg LY2157299 given orally twice daily (BID) for 14 days followed by 14 days off (28-day cycle). Participants will continue to receive until disease progression, unacceptable toxicity, or another withdrawal criterion is met.

    Drug: LY2157299

  • Experimental
    Part A Cohort 2 - 300 mg LY2157299

    150 mg LY2157299 given orally BID for 14 days followed by 14 days off (28-day cycle). Participants will continue to receive until disease progression, unacceptable toxicity, or another withdrawal criterion is met.

    Drug: LY2157299 · Drug: Sorafenib

  • Experimental
    Part B - 300 mg LY2157299

    150 mg LY2157299 given orally BID for 14 days followed by 14 days off (28-day cycle). Participants will continue to receive until disease progression, unacceptable toxicity, or another withdrawal criterion is met.

    Drug: LY2157299

  • Experimental
    Part C Cohort 1 - 160 mg LY2157299 + 800 mg Sorafenib

    80 mg LY2157299 given orally BID on Days 1 to 14 in combination with 400 mg Sorafenib BID on days 1 to 28 (28-day cycle). Participants will continue to receive until disease progression, unacceptable toxicity, or another withdrawal criterion is met.

    Drug: LY2157299 · Drug: Sorafenib

  • Experimental
    Part C Cohort 2 - 300 mg LY2157299 + 800 mg Sorafenib

    150 mg LY2157299 given orally BID on Days 1 to 14 in combination with 400 mg Sorafenib BID on days 1 to 28 (28-day cycle). Participants will continue to receive until disease progression, unacceptable toxicity, or another withdrawal criterion is met.

    Drug: LY2157299 · Drug: Sorafenib

  • Experimental
    Part D Cohort 1 - 160 mg LY2157299 + 8 mg/kg Ramucirumab

    80 mg LY2157299 given orally BID on days 1 to 14 in combination with ramucirumab 8 mg/kilogram (kg) intravenous (IV) on days 1 and 15 (28-day cycle). Participants will continue to receive until disease progression, unacceptable toxicity, or another withdrawal criterion is met.

    Drug: LY2157299 · Drug: Ramucirumab

  • Experimental
    Part D Cohort 2 - 300 mg LY2157299 + 8 mg/kg Ramucirumab

    150 mg LY2157299 given orally BID on days 1 to 14 in combination with ramucirumab 8 mg/kg IV on days 1 and 15 (28-day cycle). Participants will continue to receive until disease progression, unacceptable toxicity, or another withdrawal criterion is met.

    Drug: LY2157299 · Drug: Ramucirumab

Interventions

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Relationship of Biomarker Alpha-fetoprotein (AFP) to Overall Survival (OS)

    Biomarker response was defined as a \> 20% decrease in the biomarker AFP from baseline during 8 weeks of treatment. Data presented is median overall survival of those participants who achieved the defined biomarker response. Participants enrolled in Part A had a baseline AFP level of \>1.5 upper limit normal (ULN). Participants enrolled in Part B had baseline AFP level \<1.5 ULN.

    Time frame: Baseline, discontinuation from any cause (Up to 83 months)

  2. Change From Baseline in Relationship of Biomarker Transforming Growth Factor - Beta (TGF-β) to Overall Survival (OS)

    Biomarker response was defined as a \> 20% decrease in the biomarker TGF-B from baseline. Data presented is median overall survival of those participants who achieved biomarker response.

    Time frame: Baseline,discontinuation from any cause (Up to 83 months)

  3. Time to Progression (TTP)

    TTP is measured from the date of first dose to the first date of progression of disease based on the investigator review of tumor response using Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1). Progression is defined as at least a 20% increase in the sum of the longest diameter of target lesions, taking as reference the smallest sum on study (including the baseline sum if that is the smallest). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. The appearance of 1 or more new lesions is also considered progression.

    Time frame: Randomization to date of first measured progressive disease (Up to 36 Weeks)

Secondary outcomes

  1. Population Pharmacokinetics (PK) Mean Population Clearance of Galunisertib

    Population mean (between-subject coefficient variance \[CV %\]) apparent clearance.

    Time frame: Cycle (C) 1: Day (D)1: Predose, 0.5-2 hours(h) Postdose; D14: Predose, 0.5-2, 3-5 h, Postdose; D15 Morning; D22 Morning; Predose C2 and C3 Predose D1

  2. Recommended Dose for Phase 3 Hepatocellular Carcinoma (HCC) Trials

    Time frame: Cycle 1 (28 Days)

  3. Overall Survival (OS)

    OS duration is measured from the date of first dose to the date of death from any cause.

    Time frame: Randomization to date of death from any cause (Up to 83 months)

  4. Progression Free Survival (PFS)

    PFS duration is measure from the date of first dose to the first date of objective progression of disease or death from any cause. Progression is defined as at least a 20% increase in the sum of the longest diameter of target lesions, taking as reference the smallest sum on study (including the baseline sum if that is the smallest). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. The appearance of 1 or more new lesions is also considered progression.

    Time frame: Randomization to measured progressive disease or death from any cause (Up to 45 Weeks)

  5. Percentage of Participants Achieving an Objective Response (Response Rate)

    The percentage of participants who achieved best overall response of either Complete Response (CR) or Partial Response (PR). The overall response rate for each dose with be estimated by dividing the number of confirmed responders by the number of participants who received at least one dose of study drug. Per RECIST v.1.0 criteria CR is defined as disappearance of all target lesions. Any pathological lymph nodes (whether target or nontarget) must have reduction in short axis to \< 10 millimeter (mm). Tumor-marker results must have normalized. PR is defined as at least 30% decrease in the sum of diameter of target lesions, taking as reference the baseline sum diameters.

    Time frame: Randomization to measured progressive disease (Up to 36 Weeks)

  6. Duration of Tumor Response (DoR)

    DoR is measured from the date of the first objective status assessment of a Complete Response (CR) or Partial Response (PR), as determined by RECIST v1.1, to the first date of objective progression of disease or death from any cause. CR is defined as disappearance of all target lesions. Any pathological lymph nodes (whether target or nontarget) must have reduction in short axis to \< 10 millimeter (mm). Tumor-marker results must have normalized. PR is defined as at least 30% decrease in the sum of diameter of target lesions, taking as reference the baseline sum diameters. Progression is defined as at least a 20% increase in the sum of the longest diameter of target lesions, taking as reference the smallest sum on study (including the baseline sum if that is the smallest). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. The appearance of 1 or more new lesions is also considered progression.

    Time frame: Time of response to measured progressive disease or death from any cause (Up to 84 Weeks)

  7. Time to Treatment Failure (TTF)

    TTF is measured from the date of first dose until the date of discontinuation of study treatment due to adverse event, progression of disease, or death from any cause.

    Time frame: Randomization to the date of discontinuation of study treatment due to adverse event, progression of disease, or death from any cause (Up to 75 Weeks)

  8. Change From Baseline in Functional Assessment of Cancer Therapy, Hepatobiliary (FACT-Hep) Sub-scores and Total Score

    FACT-Hep consists of 45 items in five subscales (1) physical well-being (PWB) score rage 0 -28; (2) social well-being (SWB) score range 0-28; (3) emotional well-being (EWB) score range 0-24; (4) functional well-being (FWB) score range 0-28; and (5) the hepatobiliary cancer subscale (HCS) Score range 0-72; FACT-Hep score range 1-180, and Trial-Outcome Index (TOI) score range 1-128, to assess health related quality of life in participants with cancer. Higher scores reflect a better health state.

    Time frame: Baseline, Day 1 Cycle 4

  9. Time to Worsening (TTW) of Symptoms (FACT-Hep)

    Time to worsening of symptoms used minimally important differences to evaluate Physical Well Being (PWB), Functional Well Being (FWB), Hepatocellular Cancer Symptoms (HCS), National Comprehensive Cancer Network (NCCN)/FACT Hepatocellular Symptoms (FHS), Trial-Outcome Index (TOI). PWB time to worsening was defined as participants who had change in a subscale of ≥ 2 point decrease from baseline; FWB time to worsening was defined as participants who had change in a subscale of ≥ 2 point decrease from baseline; HCS time to worsening was defined as participants who had change in a subscale of ≥ 5 point decrease from baseline; FHS time to worsening was defined as participants who had change in a subscale of ≥ 2 point decrease from baseline; TOI time to Worsening was defined as participants who had change in the subscale of ≥ 7 point decrease from baseline.

    Time frame: Baseline to the worsening of symptoms (up to 567 days)

07

Results

Posted Aug 7, 2020
Limitations and caveats
Per the protocol, following an interim analysis, the decision was taken to no longer randomize participants to the 160 mg LY2157299 arm. Per protocol, Part D collected safety data only.

Participant flow

Participant flow — Overall Study
MilestonePart A Cohort 1 - 160 mg LY2157299Part A Cohort 2 - 300 mg LY2157299Part B - 300 mg LY2157299Part C Cohort 1 - 160 mg LY2157299 + SorafenibPart C Cohort 2 - 300 mg LY2157299 + SorafenibPart D Cohort 1 - 160 mg LY2157299 + RamucirumabPart D Cohort 2 - 300 mg LY2157299 + Ramucirumab
Started37724034435
Received at least 1 dose of study drug37724034435
Completed34673434025
Not completed3560410
Withdrew: Lost to follow-up0130010
Withdrew: Withdrawal by subject3430400

Outcome measures

PrimaryChange From Baseline in Relationship of Biomarker Alpha-fetoprotein (AFP) to Overall Survival (OS)

Biomarker response was defined as a \> 20% decrease in the biomarker AFP from baseline during 8 weeks of treatment. Data presented is median overall survival of those participants who achieved the defined biomarker response. Participants enrolled in Part A had a baseline AFP level of \>1.5 upper limit normal (ULN). Participants enrolled in Part B had baseline AFP level \<1.5 ULN.

Time frame:
Baseline, discontinuation from any cause (Up to 83 months)
Reported as:
Median · Months
Change From Baseline in Relationship of Biomarker Alpha-fetoprotein (AFP) to Overall Survival (OS)
MonthsPart A Cohort 1 - 160 mg LY2157299Part A Cohort 2 - 300 mg LY2157299Part B LY2157299Part C LY2157299
Change From Baseline in Relationship of Biomarker Alpha-fetoprotein (AFP) to Overall Survival (OS)19.0 (1.5 to 25.1)21.5 (2.9 to 34.2)24.2 (3.0 to NA)17.9 (12.6 to 32.8)
PrimaryChange From Baseline in Relationship of Biomarker Transforming Growth Factor - Beta (TGF-β) to Overall Survival (OS)

Biomarker response was defined as a \> 20% decrease in the biomarker TGF-B from baseline. Data presented is median overall survival of those participants who achieved biomarker response.

Time frame:
Baseline,discontinuation from any cause (Up to 83 months)
Reported as:
Median · Months
Change From Baseline in Relationship of Biomarker Transforming Growth Factor - Beta (TGF-β) to Overall Survival (OS)
MonthsPart A Cohort 1 - 160 mg LY2157299Part A Cohort 2 - 300 mg LY2157299Part B LY2157299Part C LY2157299
Change From Baseline in Relationship of Biomarker Transforming Growth Factor - Beta (TGF-β) to Overall Survival (OS)11.9 (5.4 to 15.6)10.1 (4.9 to 15.5)21.9 (12.4 to NA)22.88 (16.2 to 31.8)
PrimaryTime to Progression (TTP)

TTP is measured from the date of first dose to the first date of progression of disease based on the investigator review of tumor response using Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1). Progression is defined as at least a 20% increase in the sum of the longest diameter of target lesions, taking as reference the smallest sum on study (including the baseline sum if that is the smallest). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. The appearance of 1 or more new lesions is also considered progression.

Time frame:
Randomization to date of first measured progressive disease (Up to 36 Weeks)
Reported as:
Median · Weeks
Time to Progression (TTP)
WeeksPart A Cohort 1 - 160 mg LY2157299Part A Cohort 2 - 300 mg LY2157299Part B - 300 mg LY2157299Part C Cohort 1 - 160 mg + SorafenibPart C Cohort 2 - 300 mg LY2157299 + Sorafenib
Time to Progression (TTP)12.1 (6.3 to 17.6)7.1 (6.3 to 12.7)18.0 (10.0 to 24.0)36.0 (18.0 to 36.0)17.9 (12.1 to 24.0)
SecondaryPopulation Pharmacokinetics (PK) Mean Population Clearance of Galunisertib

Population mean (between-subject coefficient variance \[CV %\]) apparent clearance.

Time frame:
Cycle (C) 1: Day (D)1: Predose, 0.5-2 hours(h) Postdose; D14: Predose, 0.5-2, 3-5 h, Postdose; D15 Morning; D22 Morning; Predose C2 and C3 Predose D1
Reported as:
Geometric mean · Liter per hour (L/hr)
Population Pharmacokinetics (PK) Mean Population Clearance of Galunisertib
Liter per hour (L/hr)LY2157299
Population Pharmacokinetics (PK) Mean Population Clearance of Galunisertib33.6 ± 48
SecondaryRecommended Dose for Phase 3 Hepatocellular Carcinoma (HCC) Trials
Time frame:
Cycle 1 (28 Days)
Reported as:
Number · milligrams (mg)
Recommended Dose for Phase 3 Hepatocellular Carcinoma (HCC) Trials
milligrams (mg)LY2157299
Recommended Dose for Phase 3 Hepatocellular Carcinoma (HCC) Trials300
SecondaryOverall Survival (OS)

OS duration is measured from the date of first dose to the date of death from any cause.

Time frame:
Randomization to date of death from any cause (Up to 83 months)
Reported as:
Median · Weeks
Overall Survival (OS)
WeeksPart A Cohort 1 - 160 mg LY2157299Part A Cohort 2 - 300 mg LY2157299Part B - 300 mg LY2157299Part C Cohort 1 - 160 mg LY2157299 + SorafenibPart C Cohort 2 - 300 mg LY2157299 + Sorafenib
Overall Survival (OS)39.1 (24.1 to 52.6)29.6 (19.6 to 38.6)73.0 (45.4 to 104.7)30.3 (28.4 to 70.3)89.6 (70.3 to 104.9)
SecondaryProgression Free Survival (PFS)

PFS duration is measure from the date of first dose to the first date of objective progression of disease or death from any cause. Progression is defined as at least a 20% increase in the sum of the longest diameter of target lesions, taking as reference the smallest sum on study (including the baseline sum if that is the smallest). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. The appearance of 1 or more new lesions is also considered progression.

Time frame:
Randomization to measured progressive disease or death from any cause (Up to 45 Weeks)
Reported as:
Median · Weeks
Progression Free Survival (PFS)
WeeksPart A Cohort 1 - 160 mg LY2157299Part A Cohort 2 - 300 mg LY2157299Part B - 300 mg LY2157299Part C Cohort 1 - 160 mg LY2157299 + SorafenibPart C Cohort 2 - 300 mg LY2157299 + Sorafenib
Progression Free Survival (PFS)12 (6.3 to 12.6)6.6 (6.1 to 10.9)13.4 (7.4 to 23.3)28.4 (6.0 to 36.0)28.4 (17.4 to 45.3)
SecondaryPercentage of Participants Achieving an Objective Response (Response Rate)

The percentage of participants who achieved best overall response of either Complete Response (CR) or Partial Response (PR). The overall response rate for each dose with be estimated by dividing the number of confirmed responders by the number of participants who received at least one dose of study drug. Per RECIST v.1.0 criteria CR is defined as disappearance of all target lesions. Any pathological lymph nodes (whether target or nontarget) must have reduction in short axis to \< 10 millimeter (mm). Tumor-marker results must have normalized. PR is defined as at least 30% decrease in the sum of diameter of target lesions, taking as reference the baseline sum diameters.

Time frame:
Randomization to measured progressive disease (Up to 36 Weeks)
Reported as:
Number · percentage of participants
Percentage of Participants Achieving an Objective Response (Response Rate)
percentage of participantsPart A Cohort 1 - 160 mg LY2157299Part A Cohort 2 - 300 mg LY2157299Part B - 300 mg LY2157299Part C Cohort 1 - 160 mg LY2157299 + SorafenibPart C Cohort 2 - 300 mg LY2157299 + Sorafenib
Complete Response00000
Partial Response003.702.3
SecondaryDuration of Tumor Response (DoR)

DoR is measured from the date of the first objective status assessment of a Complete Response (CR) or Partial Response (PR), as determined by RECIST v1.1, to the first date of objective progression of disease or death from any cause. CR is defined as disappearance of all target lesions. Any pathological lymph nodes (whether target or nontarget) must have reduction in short axis to \< 10 millimeter (mm). Tumor-marker results must have normalized. PR is defined as at least 30% decrease in the sum of diameter of target lesions, taking as reference the baseline sum diameters. Progression is defined as at least a 20% increase in the sum of the longest diameter of target lesions, taking as reference the smallest sum on study (including the baseline sum if that is the smallest). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. The appearance of 1 or more new lesions is also considered progression.

Time frame:
Time of response to measured progressive disease or death from any cause (Up to 84 Weeks)
Reported as:
Median · Weeks
Duration of Tumor Response (DoR)
WeeksPart A Cohort 1 - 160 mg LY2157299Part A Cohort 2 - 300 mg LY2157299Part B - 300 mg LY2157299Part C Cohort 1 - 160 mg LY2157299 + SorafenibPart C Cohort 2 - 300 mg LY2157299 + Sorafenib
Duration of Tumor Response (DoR)——37.6 (25.1 to 50.1)—40.2 (12.1 to 84.1)
SecondaryTime to Treatment Failure (TTF)

TTF is measured from the date of first dose until the date of discontinuation of study treatment due to adverse event, progression of disease, or death from any cause.

Time frame:
Randomization to the date of discontinuation of study treatment due to adverse event, progression of disease, or death from any cause (Up to 75 Weeks)
Reported as:
Median · Weeks
Time to Treatment Failure (TTF)
WeeksPart A Cohort 1 - 160 mg LY2157299Part A Cohort 2 - 300 mg LY2157299Part B - 300 mg LY2157299Part C Cohort 1 - 160 mg LY2157299 + SorafenibPart C Cohort 2 - 300 mg LY2157299 + Sorafenib
Time to Treatment Failure (TTF)13.4 (8.6 to 18.0)9.9 (8.1 to 12.1)19.3 (12.1 to 26.3)26.3 (19.3 to 54.0)49.3 (18.3 to 75.3)
SecondaryChange From Baseline in Functional Assessment of Cancer Therapy, Hepatobiliary (FACT-Hep) Sub-scores and Total Score

FACT-Hep consists of 45 items in five subscales (1) physical well-being (PWB) score rage 0 -28; (2) social well-being (SWB) score range 0-28; (3) emotional well-being (EWB) score range 0-24; (4) functional well-being (FWB) score range 0-28; and (5) the hepatobiliary cancer subscale (HCS) Score range 0-72; FACT-Hep score range 1-180, and Trial-Outcome Index (TOI) score range 1-128, to assess health related quality of life in participants with cancer. Higher scores reflect a better health state.

Time frame:
Baseline, Day 1 Cycle 4
Reported as:
Mean · units on a scale
Change From Baseline in Functional Assessment of Cancer Therapy, Hepatobiliary (FACT-Hep) Sub-scores and Total Score
units on a scalePart A Cohort 1 - 160 mg LY2157299Part A Cohort 2 - 300 mg LY2157299Part B - 300 mg LY2157299Part C Cohort 1 - 160mg LY2157299 + SorafenibPart C Cohort 2 - 300 mg LY2157299 + Sorafenib
PWB0.06 ± 3.6-0.16 ± 5.00.04 ± 3.4-1.67 ± 1.5-1.75 ± 4.4
SWB0.96 ± 2.90.24 ± 3.40.37 ± 4.5-1.11 ± 2.80.41 ± 3.6
EWB0.55 ± 2.71.17 ± 3.91.13 ± 4.12.87 ± 2.80.85 ± 2.5
FWB-0.02 ± 5.30.84 ± 3.61.20 ± 4.7-1.00 ± 1.0-1.19 ± 4.6
HCS1.93 ± 7.61.40 ± 7.80.89 ± 6.81.08 ± 6.0-3.79 ± 7.3
FACT-Hep2.04 ± 1.531.50 ± 17.50.58 ± 18.2-0.50 ± 6.5-8.54 ± 17.0
TOI1.34 ± 13.31.14 ± 14.61.17 ± 12.2-1.92 ± 7.7-8.28 ± 13.7
SecondaryTime to Worsening (TTW) of Symptoms (FACT-Hep)

Time to worsening of symptoms used minimally important differences to evaluate Physical Well Being (PWB), Functional Well Being (FWB), Hepatocellular Cancer Symptoms (HCS), National Comprehensive Cancer Network (NCCN)/FACT Hepatocellular Symptoms (FHS), Trial-Outcome Index (TOI). PWB time to worsening was defined as participants who had change in a subscale of ≥ 2 point decrease from baseline; FWB time to worsening was defined as participants who had change in a subscale of ≥ 2 point decrease from baseline; HCS time to worsening was defined as participants who had change in a subscale of ≥ 5 point decrease from baseline; FHS time to worsening was defined as participants who had change in a subscale of ≥ 2 point decrease from baseline; TOI time to Worsening was defined as participants who had change in the subscale of ≥ 7 point decrease from baseline.

Time frame:
Baseline to the worsening of symptoms (up to 567 days)
Reported as:
Median · Days
Time to Worsening (TTW) of Symptoms (FACT-Hep)
DaysPart A Cohort 1 - 160 mg LY2157299Part A Cohort 2 - 300 mg LY2157299Part B - 300 mg LY2157299Part C Cohort 2 - 300mg LY2157299
PWB114.0 (30.0 to NA)113.0 (57.0 to NA)113.0 (58.0 to 170.0)30.0 (29.0 to 57.0)
FWB57.0 (30.0 to 86.0)88.0 (57.0 to 371.0)64.0 (30.0 to 172.0)30.0 (29.0 to 58.0)
HCS114.0 (57.0 to NA)113.0 (85.0 to NA)170.0 (57.0 to 567.0)31.0 (29.0 to 57.0)
FHS55.0 (29.0 to 86.0)57.0 (30.0 to 113.0)57.0 (30.0 to 113.0)30.0 (29.0 to 30.0)
TOI114.0 (57.0 to NA)113.0 (58.0 to 371.0)179.0 (57.0 to 567.0)30.0 (29.0 to 31.0)

Adverse events

Collected over Baseline up to 41.5 months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Part A Cohort 1 - 160 mg LY215729933/37 (89.2%)15/37 (40.5%)32/37 (86.5%)
Part A Cohort 2 - 300 mg LY215729963/72 (87.5%)36/72 (50%)64/72 (88.9%)
Part B - 300 mg LY215729926/40 (65%)16/40 (40%)38/40 (95%)
Part C Cohort 1 - 160 mg LY2157299 + Sorafenib3/3 (100%)3/3 (100%)3/3 (100%)
Part C Cohort 2 - 300 mg LY2157299 + Sorafenib36/44 (81.8%)28/44 (63.6%)44/44 (100%)
Part D Cohort 1 - 160 mg LY2157299 + Ramucirumab2/3 (66.7%)1/3 (33.3%)3/3 (100%)
Part D Cohort 2 - 300 mg LY2157299 + Ramucirumab5/5 (100%)2/5 (40%)5/5 (100%)
Most frequent serious events
Showing 10 of 127
Most frequent serious events
EventPart A Cohort 1 - 160 mg LY2157299Part A Cohort 2 - 300 mg LY2157299Part B - 300 mg LY2157299Part C Cohort 1 - 160 mg LY2157299 + SorafenibPart C Cohort 2 - 300 mg LY2157299 + SorafenibPart D Cohort 1 - 160 mg LY2157299 + RamucirumabPart D Cohort 2 - 300 mg LY2157299 + Ramucirumab
AnaemiaBlood and lymphatic system disorders2/377/723/401/36/440/30/5
Duodenal ulcerGastrointestinal disorders0/370/720/401/30/440/30/5
Gastrointestinal haemorrhageGastrointestinal disorders0/371/721/401/30/440/31/5
Upper gastrointestinal haemorrhageGastrointestinal disorders0/371/722/401/31/440/30/5
General physical health deteriorationGeneral disorders0/370/720/401/30/440/30/5
Second primary malignancyNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/370/720/401/30/440/30/5
Embolic strokeNervous system disorders0/370/720/400/30/441/30/5
Renal injuryRenal and urinary disorders0/370/720/401/30/440/30/5
Pulmonary embolismRespiratory, thoracic and mediastinal disorders1/370/722/401/31/440/30/5
Acute hepatic failureHepatobiliary disorders0/370/720/400/30/440/31/5
Most frequent other events
Showing 10 of 90
Most frequent other events
EventPart A Cohort 1 - 160 mg LY2157299Part A Cohort 2 - 300 mg LY2157299Part B - 300 mg LY2157299Part C Cohort 1 - 160 mg LY2157299 + SorafenibPart C Cohort 2 - 300 mg LY2157299 + SorafenibPart D Cohort 1 - 160 mg LY2157299 + RamucirumabPart D Cohort 2 - 300 mg LY2157299 + Ramucirumab
Weight decreasedInvestigations4/378/7210/403/324/440/30/5
EpistaxisRespiratory, thoracic and mediastinal disorders1/372/723/400/34/443/31/5
FlatulenceGastrointestinal disorders2/370/721/402/33/440/30/5
FatigueGeneral disorders9/3714/7214/402/311/440/32/5
Decreased appetiteMetabolism and nutrition disorders6/377/727/402/310/440/30/5
Musculoskeletal chest painMusculoskeletal and connective tissue disorders0/372/721/400/31/442/30/5
Palmar-plantar erythrodysaesthesia syndromeSkin and subcutaneous tissue disorders0/371/721/401/328/440/30/5
DiarrhoeaGastrointestinal disorders5/3710/7211/401/321/441/31/5
Abdominal distensionGastrointestinal disorders2/372/725/400/34/441/32/5
Abdominal painGastrointestinal disorders7/3711/728/401/37/440/32/5

Baseline characteristics

All enrolled participants.

Age, Continuous
Age, Continuous(years)Part A Cohort 1 - 160 mg LY2157299Part A Cohort 2 - 300 mg LY2157299Part B - 300 mg LY2157299Part C Cohort 1 - 160 mg LY2157299 + SorafenibPart C Cohort 2 - 300 mg LY2157299 + SorafenibPart D Cohort 1 - 160 mg LY2157299 + RamucirumabPart D Cohort 2 - 300 mg LY2157299 + RamucirumabTotal
Mean63.4 ± 10.863.3 ± 10.868.1 ± 9.670.3 ± 4.763.7 ± 9.854.0 ± 11.363.2 ± 11.264.3 ± 10.5
Sex: Female, Male
Sex: Female, Male(Participants)Part A Cohort 1 - 160 mg LY2157299Part A Cohort 2 - 300 mg LY2157299Part B - 300 mg LY2157299Part C Cohort 1 - 160 mg LY2157299 + SorafenibPart C Cohort 2 - 300 mg LY2157299 + SorafenibPart D Cohort 1 - 160 mg LY2157299 + RamucirumabPart D Cohort 2 - 300 mg LY2157299 + RamucirumabTotal
Female5134050027
Male32593633935177
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Part A Cohort 1 - 160 mg LY2157299Part A Cohort 2 - 300 mg LY2157299Part B - 300 mg LY2157299Part C Cohort 1 - 160 mg LY2157299 + SorafenibPart C Cohort 2 - 300 mg LY2157299 + SorafenibPart D Cohort 1 - 160 mg LY2157299 + RamucirumabPart D Cohort 2 - 300 mg LY2157299 + RamucirumabTotal
American Indian or Alaska Native00010001
Asian171062421
Native Hawaiian or Other Pacific Islander02007009
Black or African American23102019
White34583522000149
More than one race00000000
Unknown or Not Reported023091015
Region of Enrollment
Region of Enrollment(Participants)Part A Cohort 1 - 160 mg LY2157299Part A Cohort 2 - 300 mg LY2157299Part B - 300 mg LY2157299Part C Cohort 1 - 160 mg LY2157299 + SorafenibPart C Cohort 2 - 300 mg LY2157299 + SorafenibPart D Cohort 1 - 160 mg LY2157299 + RamucirumabPart D Cohort 2 - 300 mg LY2157299 + RamucirumabTotal
New Zealand2540120023
United States61241103541
Italy12159040040
Australia03200005
France1227160140069
Germany474240021
Spain13100005
Alpha-Fetoprotein
Alpha-Fetoprotein(Participants)Part A Cohort 1 - 160 mg LY2157299Part A Cohort 2 - 300 mg LY2157299Part B - 300 mg LY2157299Part C Cohort 1 - 160 mg LY2157299 + SorafenibPart C Cohort 2 - 300 mg LY2157299 + SorafenibPart D Cohort 1 - 160 mg LY2157299 + RamucirumabPart D Cohort 2 - 300 mg LY2157299 + RamucirumabTotal
< 200 nanograms per Liter (µg/L)923282201285
200 - 400 (µg/L)350040012
> 400 (µg/L)234301162287
Unknown/Not reported2112040120
08

Study locations

40 sites
  • Highlands Oncology Group
    Fayetteville, Arkansas 72703, United States
  • University of California, San Francisco
    San Francisco, California 94158, United States
  • Georgetown University Medical Center
    Washington, District of Columbia 20007, United States
  • MD Anderson Cancer Center Orlando
    Orlando, Florida 32806, United States
  • Northwestern University
    Chicago, Illinois 60611, United States
  • Indiana Univ Melvin & Bren Simon Cancer Center
    Indianapolis, Indiana 46202, United States
  • Lahey Clinic Medical Center
    Burlington, Massachusetts 01805, United States
  • Weill Cornell Medical College
    New York, New York 10021, United States
  • Memorial Sloan Kettering Cancer Center
    New York, New York 10065, United States
  • Thomas Jefferson University
    Philadelphia, Pennsylvania 19107, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Nedlands, Western Australia 6009, Australia
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Greenslopes, 4120, Australia
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician
    Heidelberg, 3084, Australia
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    St. Leonards, 2065, Australia
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Brest, 29609, France
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Caen, 14033, France
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Clichy, 92110, France
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Creteil, 94010, France
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Lille, 59037, France
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Lyon, 69317, France
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Marseille, 13273, France
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Montpellier, 34295, France
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Paris, 75012, France
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Pessac, 33604, France
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician
    Saint Etienne, 42055, France
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Saint Herblain, 44805, France
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Strasbourg, 67085, France
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Vandoeuvre Les Nancy, 54511, France
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Berlin, 13353, Germany
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Erlangen, 91054, Germany
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Göttingen, 37075, Germany
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Köln, 50937, Germany
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Mainz, 55131, Germany
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Münster, 48149, Germany
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Bari, 70124, Italy
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Rome, 00168, Italy
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Rozzano, 20089, Italy
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Auckland, 1023, New Zealand
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Barcelona, 08035, Spain
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Madrid, 28007, Spain
09

References and documents

Publications

  • Giannelli G, Santoro A, Kelley RK, Gane E, Paradis V, Cleverly A, Smith C, Estrem ST, Man M, Wang S, Lahn MM, Raymond E, Benhadji KA, Faivre S. Biomarkers and overall survival in patients with advanced hepatocellular carcinoma treated with TGF-betaRI inhibitor galunisertib. PLoS One. 2020 Mar 25;15(3):e0222259. doi: 10.1371/journal.pone.0222259. eCollection 2020. Erratum In: PLoS One. 2020 Jun 25;15(6):e0235580. doi: 10.1371/journal.pone.0235580. PLoS One. 2021 Jun 17;16(6):e0253671. doi: 10.1371/journal.pone.0253671. PubMed 32210440 ↗
  • Addepalli A, Kalyani S, Singh M, Bandyopadhyay D, Mohan KN. CalPen (Calculator of Penetrance), a web-based tool to estimate penetrance in complex genetic disorders. PLoS One. 2020 Jan 29;15(1):e0228156. doi: 10.1371/journal.pone.0228156. eCollection 2020. Erratum In: PLoS One. 2020 Jun 25;15(6):e0235547. doi: 10.1371/journal.pone.0235547. PubMed 31995602 ↗
  • Faivre S, Santoro A, Kelley RK, Gane E, Costentin CE, Gueorguieva I, Smith C, Cleverly A, Lahn MM, Raymond E, Benhadji KA, Giannelli G. Novel transforming growth factor beta receptor I kinase inhibitor galunisertib (LY2157299) in advanced hepatocellular carcinoma. Liver Int. 2019 Aug;39(8):1468-1477. doi: 10.1111/liv.14113. Epub 2019 Jun 3. PubMed 30963691 ↗
  • Li S, Yang F, Ren X. Immunotherapy for hepatocellular carcinoma. Drug Discov Ther. 2015 Oct;9(5):363-71. doi: 10.5582/ddt.2015.01054. PubMed 26632545 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: Data are available 6 months after the primary publication and approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting.

Access criteria: A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.

Data sharing details ↗ · vivli.org

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2011 to primary completion in Jun 2019, 98 months.

Results were first posted in Aug 2020, 1 year 2 months after primary completion.

Of 80 industry-sponsored phase 2 interventional studies under Carcinoma, Hepatocellular, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 50. This study's 98 months is above that.

Counting every sponsor, half of 429 studies reached it within 43 months; a quarter within 30 and three quarters within 71.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 1, 2010
First posted
Nov 24, 2010
StartActual
Mar 30, 2011
Primary completionActual
Jun 6, 2019
CompletionActual
Dec 24, 2019
Results first posted
Aug 7, 2020
Last update
Jan 12, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 12, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01246986
Responsible party
Sponsor
First posted
Nov 24, 2010
Start date
Mar 30, 2011
Primary completion
Jun 6, 2019
Completion
Dec 24, 2019
Results posted
Aug 7, 2020
Last update
Jan 12, 2021

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: LY-2157299

Start the discussion